anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicinal microbiology, immunology. SUBSTANCE: method involves preliminary quantitative estimation of immunogenicity of the analyzed culture population by relative amount of toxin-producing colony-forming units in vitro on agar for immunological investigation. Low- and nonimmunogenic cultures were excluded from the further study of immunogenicity in vivo. Then method involves selection of immunogenic cultures, selection in population of lowimmunogenic and nonimmunogenic cultures of immunogenic clones, preparing cultures for the following confirmation of their immunogenicity and final selection in vivo. Invention ensures to increase effectiveness of selection by two-fold, decrease consumption of experimental animals by two-fold and enhance immunogenicity of cultures. EFFECT: improved method of selection. 2 tbl
The invention discloses coconut peptide water beverage which is mainly composed of a coconut extract and an accessory. The accessory comprises a sweetener, citric acid, table salt and a thickener. The weight ratio of the above ingredients is as follows: the coconut extract: 0.1 to 20%; the sweetener: 0.01 to 10%; the citric acid: 0.01 to 0.5%; the thickener: 0.01 to 0.5%; the table salt: 0.01 to 0.5%; and the rest is water. The coconut extract is adopted as the main raw material, and a food additive is added for blending, split charging and sterilizing, so as to obtain the coconut peptide water beverage which mainly contains diversified nutritious and health care ingredients such as amino acid, polypeptide, microelements and the like. The invention further discloses a preparation method and a purpose of the coconut peptide water beverage. The beverage is good for both children and adults, and has the functions as well as effects of refreshing, detoxifying, invigorating the spleen, promoting appetite, resisting fatigue, enhancing immunity, resisting ageing and the like. With the characteristics of golden luster, distinctive taste, high nutritive value and no pollution, the healthy coconut peptide water beverage is a pure green product for people all the year round.
The invention relates to a mutant C beta  protein comprising the amino acid sequence A-X1X2X3X4X5X6X7X8X9X10X11X12-B, wherein A comprises amino acids 1-164 of the sequence shown in Fig. 1 (SEQ ID NO: 2), B represents a sequence starting from amino acid 177 and terminating at an amino acid between residue 1094 and 1127, inclusive, of the sequence shown in Fig. 1 (SEQ ID NO: 2), and X1 - X12 are each selected independently from the group consisting of Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, a bond, and the wild type amino acid found at the corresponding position of the sequence shown in Fig. 1 (SEQ ID NO: 2), wherein said amino acid positions are numbered from the first amino acid of the native amino acid sequence encoding said protein, with the proviso that at least one of X1 through X12, inclusive, is other than the wild type amino acid, and wherein the LPXTG motif may be missing from the mutant C beta  protein. The invention also relates to a polynucleotide molecule encoding a mutant C beta  protein, as well as vectors comprising such polynucleotide molecules, and host cells transformed therewith. The invention also relates to a conjugate comprising the mutant C beta  protein covalently conjugated to a capsular polysaccharide. The invention also relates to a vaccine comprising at least one mutant C beta  protein of the invention and a pharmaceutically acceptable carrier. The invention also relates to a method of inducing an immune response in an animal, comprising administering the vaccine of the invention to an animal in a therapeutically effective amount.
Hypertrophic scars, which result from aberrant fibrosis and disorganized collagen synthesis by skin fibroblasts, emerge due to disrupted wound healing processes. These scars present significant psychosocial and functional challenges to affected individuals. The current treatment limitations largely arise from an incomplete understanding of the underlying mechanisms of hypertrophic scar development. Recent studies, however, have shed light on the potential of exosomal non‑coding RNAs interventions to mitigate hypertrophic scar proliferation. The present study assessed the impact of exosomes derived from adipose‑derived stem cells (ADSCs‑Exos) on hypertrophic scar formation using a rabbit ear model. It employed hematoxylin and eosin staining, Masson's trichrome staining and immunohistochemical staining techniques to track scar progression. The comprehensive analysis of the present study encompassed the differential expression of non‑coding RNAs, enrichment analyses of functional pathways, protein‑protein interaction studies and micro (mi)RNA‑mRNA interaction investigations. The results revealed a marked alteration in the expression levels of long non‑coding RNAs and miRNAs following ADSCs‑Exos treatment, with little changes observed in circular RNAs. Notably, miRNA (miR)‑194 emerged as a critical regulator within the signaling pathways that govern hypertrophic scar formation. Dual‑luciferase assays indicated a significant reduction in the promoter activity of TGF‑β1 following miR‑194 overexpression. Reverse transcription‑quantitative PCR and immunoblotting assays further validated the decrease in TGF‑β1 expression in the treated samples. In addition, the treatment resulted in diminished levels of inflammatory markers IL‑1β, TNF‑α and IL‑10. In vivo evidence strongly supported the role of miR‑194 in attenuating hypertrophic scar formation through the suppression of TGF‑β1. The present study endorsed the strategic use of ADSCs‑Exos, particularly through miR‑194 modulation, as an effective strategy for reducing scar formation and lowering pro‑inflammatory and fibrotic indicators such as TGF‑β1. Therefore, the present study advocated the targeted application of ADSCs‑Exos, with an emphasis on miR‑194 modulation, as a promising approach to managing proliferative scarring.
Total parenteral nutrition is an essential component of the care of premature and ill infants. Prolonged parenteral nutrition is associated with complications affecting the hepatobiliary system, such as cholelithiasis, cholestasis, and steatosis. The most common of these is total parenteral nutrition-associated cholestasis (TPNAC), that occurs because of reduced bile flow from the liver into the duodenum. Cholestasis causes liver damage and in some cases, death. Infant and neonate are at particular risk for this complication. The incidence of TPNAC ranges from 7.4 to 84%.

Animal studies have implicated amino acids in the production of cholestasis; whereas studies in human neonates suggest a direct effect of amino acid infusions on the hepatocyte canalicular membrane. An appropriate amino acid solution might compensate for the metabolic immaturity of infants and perhaps reduce total parenteral nutrition associated complications such as cholestasis. Therefore, is important to compare the frequency of cholestasis and blood amino acid concentration during Primene and Trophamine use.
PURPOSE:To obtain the titled pharmaceutical having excellent solubility in using, maintaining particle size distribution of liposome particle also after dissolving and free from change of including ratio of superoxide dimustase (SOD), by dispersing SODretaining liposome pharmaceutical containing stearyl amine as membrane material and saccharides into an aqueous medium and lyophilizing the dispersion. CONSTITUTION:A superoxide dimustase (SOD)-retaining liposome pharmaceutical consisting of a liposome membrane material obtained by adding 0.1-0.8pts.wt. stearyl amine to 1pts.wt. phospholipid and saccharides selected from grape sugar, sugar and trehalose are dispersed into an aqueous medium (e.g., water or physiological saline) and lyophilized e.g., at -20--50 deg.C and then dried under reduced pressure of <=0.1Torr. The saccharides and aqueous medium are each preferably used in amounts of 1-10pts.wt. and 3-5pts.wt. based on 1pts.wt. phospholipid of the liposome pharmaceutical.
Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
The invention relates to an interactive multimedia medical report system comprising a test unit, a marking unit, a database, and an electronic device. The test unit is configured to generate an image. The marking unit is configured to establish a predefined tag at a first position of the image and a special tag at a second position of the image. The database is connected to the marking unit and stores the medical report comprising the image for at least one of the predefined tag and the special tags. The electronic device comprises a processing unit that is connected with the database through the communication unit to retrieve the medical report. The electronic device further comprises a display unit configured to show at least one of the predefined tag and the special tag of the image. In addition, the invention further provides a multimedia interaction medical report method.
Self-stigma beliefs are common among people with visible chronic skin diseases and can negatively affect their quality of life and psychosocial wellbeing. Hence, evidence-based interventions are urgently needed. The objective for this systematic review was to summarize research on available interventions and evaluate their benefits and limitations. Following PRISMA guidelines, we conducted an electronic database search of four databases (EMBASE, PsycINFO, PubMed, Web of Science). Studies were eligible if they (a) investigated interventions to reduce self-stigma in adults with chronic skin disease, (b) were original empirical articles, and (c) were written in English or German. Two independent reviewers conducted the abstract and full text screening as well as data extraction. The quality of the included studies was evaluated using the Critical Appraisal Skills Programme checklists. The initial search yielded 5811 abstracts; of which, 23 records were eligible. Studies addressed a broad range of skin conditions, and interventions ranged from social skills training, counselling and self-help to psychosocial and behavioural interventions. Overall, interventions had mostly positive effects on self-stigma and related constructs. However, the study quality was heterogeneous, and further efforts to develop, thoroughly evaluate and implement interventions tackling self-stigma in multiple skin conditions and languages are warranted.
The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector monitors iontophoretic medicament migration into the skin. An integrator operating on the output of the detector produces a running cumulative total of the amount of medicament delivered during a plurality of temporally non-contiguous therapy subsessions. A circuit breaker terminates medicament migration, when the output of the integrator equals a predetermined medicament quantity. A timer active during medicament migration stimulates a driver to operate a light-emitting diode in a distinct delivery confirmation mode during each a sequence of non-overlapping predetermined therapy subsessions, respectively. A circuit board on the substrate in a compact, folded state bears interconnected electrical circuit components.
Two-year carcinogenicity studies with pramipexole have been conducted in mice and rats. Pramipexole was administered in the diet to mice at doses up to 10 mg/kg/day (or approximately 10 times the maximum recommended human dose (MRHD) for Parkinson’s disease of 4.5 mg/day on a mg/m2 basis). Pramipexole was administered in the diet to rats at doses up to 8 mg/kg/day. These doses were associated with plasma AUCs up to approximately 12 times that in humans at the MRHD. No significant increases in tumors occurred in either species. 

Pramipexole was not mutagenic or clastogenic in a battery of in vitro (bacterial reverse mutation, V79/HGPRT gene mutation, chromosomal aberration in CHO cells) and in vivo (mouse micronucleus) assays. 

In rat fertility studies, pramipexole at a dose of 2.5 mg/kg/day (5 times the MRHD on a mg/m2 basis) prolonged estrus cycles and inhibited implantation. These effects were associated with reductions in serum levels of prolactin, a hormone necessary for implantation and maintenance of early pregnancy in rats.
Liquid make-up is a cosmetic product for make-up and the decoration of the face with a multi-functional use. Organoieptically it appears liquid, coloured and semi-transparent. On application it is filmy, soft, sheer and supple. Once the product has been applied it is smudge-proof, water-resistant, non-toxic and does not block pores. It is easy to use, it dries quickly, is easily removed and can be touched up. The product's formula consists of the following components: a) polymeric complex that forms an impalpable and water-resistant film; b) a mix of short chain esters with plasticizing action; c) water-soluble pigments; d) scent; e) antifungal and antibacterial preservatives; f) water; g) various additives.
The recommended dose of BROVANA (arformoterol tartrate) Inhalation Solution is one 15 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended.

BROVANA Inhalation Solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor (see the accompanying Patient Information). BROVANA Inhalation Solution should not be swallowed. BROVANA Inhalation Solution should be stored refrigerated in foil pouches. After opening the pouch, unused unit-dose vials should be returned to, and stored in, the pouch. An opened unit-dose vial should be used right away.

If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be reevaluated and additional therapeutic options should be considered.

No dose adjustment is required for patients with renal or hepatic impairment. However, since the clearance of BROVANA Inhalation Solution is prolonged in patients with hepatic impairment, they should be monitored closely.

The drug compatibility (physical and chemical), efficacy, and safety of BROVANA Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

The safety and efficacy of BROVANA Inhalation Solution have been established in clinical trials when administered using the PARI LC® Plus nebulizer (with a face mask or mouthpiece) and the PARI DURA NEB™ 3000 compressor. The safety and efficacy of BROVANA Inhalation Solution delivered from non-compressor based nebulizer systems have not been established.
BACKGROUND: Lead (Pb) is an ancient toxic metal and is still a major public health issue. Our previous study found that Pb exposure promotes metabolic disorders in obese mice, but the molecular mechanisms remain unclear. The present study explored the effects of Pb exposure on glucose homeostasis in mice fed a normal diet (ND) and high-fat diet (HFD) from the perspective of gut microbiota.
RESULTS: Pb exposure had little effect on glucose metabolism in ND mice, but exacerbated hyperglycemia and insulin resistance, and impaired glucose tolerance in HFD mice. Pb exposure impaired intestinal tight junctions and mucin expression in HFD mice, increasing intestinal permeability and inflammation. Moreover, Pb exposure altered the composition and structure of the gut microbiota and decreased short-chain fatty acids (SCFAs) levels in HFD mice. Correlation analysis revealed that the gut microbiota and SCFAs were significantly correlated with the gut barrier and glucose homeostasis. Furthermore, the fecal microbiota transplantation from Pb-exposed HFD mice resulted in glucose homeostasis imbalance, intestinal mucosal structural damage and inflammation in recipient mice. However, Pb did not exacerbate the metabolic toxicity in HFD mice under depleted gut microbiota.
CONCLUSION: The findings of the present study suggest that Pb induces impairment of glucose metabolism in HFD mice by perturbing the gut microbiota. Our study offers new perspectives on the mechanisms of metabolic toxicity of heavy metals and demonstrates that the gut microbiota may be a target of action for heavy metal exposure. © 2023 Society of Chemical Industry.
The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that cDNA and hosts transformed with those recombinant cDNA molecules. This invention further related to novel methods for screening for variants of a strain 3 poliovirus. This invention also related to methods for increasing the attenuation of a strain poliovirus. This invention provides a vaccine useful for immunizing a subject, for example a human, against infectious poliovirus, wherein the vaccine comprises an effective amount of an RNA virus, produced by transforming a suitable host cell with a recombinant nucleic acid sequence which encodes for the virus: culturing the host cell under conditions which permit the production of virus: and isolating the virus so produced, effective to immunize the subject, and a suitable carrier. Further provided to this invention is a method of immunizing a subject such as a human against infectious poliovirus, wherein the method comprises administering the subject a suitable dose of the vaccine described hereinabove.
The invention relates to the application for concave or annular particles of silicone materials for increasing the sun protection factor (SPF), in which the particles exist in the compositions notably the form of part hollow sphere. The compositions contain at least one aqueous phase, at least one organic UV screening agent and/or at least one inorganic UV screening agent. Another subject of the invention is concave or annular particles of silicone materials decreasing illumination after being used. The particles, notably the form of part hollow sphere exist in the compositions with at least one wetting agent combination. The compositions contain at least one aqueous phase and one organic UV screening agent and/or at least one inorganic UV screening agent in physiologically acceptable medium. The invention also relates to one composition including a) at least one aqueous phase; b) concave or annular particles of silicone materials, especially the form of part hollow sphere; c) at least one wetting agent; d) at least one organic UV screening agent and/or at least one inorganic UV screening agent in the physiologically acceptable medium.
The invention relates to peptides and peptide derivatives based on the naturally occurring peptide xenin. The invention provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence, the peptide having one or more lysine residues substituted with a lipophilic substituent of 840 carbon atoms, optionally via a spacer. The present invention also provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence and in which one or more of Lys 4 , Lys 8 , Arg 11 , Lys 13 , Phe 17 , Lys 20 , or Arg 21  have been replaced with another amino acid which increases resistance of the peptide to enzymatic degradation. Further provided are molecules and formulations comprising these peptides and therapeutic uses of these peptides.
Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
The invention discloses hydrophobic drug nanoparticles as well as a preparation method and application thereof. The hydrophobic drug nanoparticles are in a spherical or near-spherical shape. The hydrophobic drug nanoparticles are prepared by the following processes: preparing precursor nanoparticle suspended emulsion from hydrophobic drug molecules by a solvent exchange method; adding an amphipathic surfactant water solution to the precursor nanoparticle suspended emulsion; carrying out ultrasonic treatment, so as to obtain the nanoparticles coated with the amphipathic surfactant at the surface. The hydrophobic drug nanoparticles have the characteristics of high bioavailability and high drug loading capacity. The method is simple to operate, wide in application range, and strong in universality. The hydrophobic drug nanoparticles can be applied to the fields of biomedicine and pharmaceutical preparations.
PROBLEM TO BE SOLVED: To obtain composite powder giving natural finishing of almost bare skin while covering weak point of the skin when mixing as a powder component of a makeup cosmetic by covering a specific amount of hollow spherical resin powder on the surface of filmy powder as a substrate. SOLUTION: This composite powder is obtained by using (A) filmy powder as a substrate and covering the surface of the component A with (B) hollow spherical resin powder. A weight ratio of the components A/B is (80/20)-(20/80). Preferably, the component A has 1-80 μm average particle diameter. Preferably, mica titanium is combinedly used with another filmy powder such as talc or mica, as the component A. As the component B, hollow spherical fine particle of a styrene-acrylic copolymer resin is preferable. Preferably, the component B has 0.1-0.5 μm average hollow diameter and 0.3-1.5 μm average particle diameter. The powder may be obtained by mixing the component A with the component B, slurrying in an alcohol aqueous solution and spray drying at 70-100 deg.C.